Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monsenso ASOCSE:MONSO +8.89%27 Debt-to-Equity is 0.26 as of Dec. 2025, which is 69% below its 10-year median of 0.85. GuruFocus rates OCSE:MONSO with a GF Score™ of 27/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 557 Healthcare Providers & Services companies, Monsenso AS ranks better than 62.48% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Monsenso AS's Debt-to-Equity or its related term are showing as below:
OCSE:MONSO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.26 Med: 0.85 Max: 1.05
Current: 0.26
During the past 9 years, the highest Debt-to-Equity Ratio of Monsenso AS was 1.05. The lowest was 0.26. And the median was 0.85.
OCSE:MONSO's Debt-to-Equity is ranked better than 62.48% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.41
vs OCSE:MONSO: 0.26
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Monsenso AS Debt-to-Equity Related Terms
Monsenso AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Monsenso AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, HQY: Debt-to-Equity Comparison
For the Health Information Services subindustry, Monsenso AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Monsenso AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monsenso AS (OCSE:MONSO) has a Debt-to-Equity of 0.26 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Monsenso AS and its competitors. This is 69% below median its historical median of 0.85. Over the past decade, Monsenso AS's Debt-to-Equity has ranged from 0.26 to 1.05. According to the industry distribution chart, Monsenso AS ranks #209 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 37.5%.
Is Monsenso AS's Debt-to-Equity too high?
Monsenso AS's current Debt-to-Equity of 0.26 is 69% below median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 1.05. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. Monsenso AS's value of 0.26 is 36.6% below this industry median. Based on the distribution chart, Monsenso AS ranks #209 out of 557 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Monsenso AS has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's Debt-to-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #209 out of 557 companies for Debt-to-Equity. This puts Monsenso AS in the upper half of its industry. The industry median Debt-to-Equity is 0.41. Monsenso AS's value of 0.26 is 36.6% below this benchmark. Historically, Monsenso AS's own Debt-to-Equity has ranged from 0.26 to 1.05 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.41, Monsenso AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monsenso AS's current Debt-to-Equity of 0.26 is 36.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Monsenso AS and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current Debt-to-Equity is 0.26, which is 69% below median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.29 — trading 96% above its estimated fair value. The current Debt-to-Equity is 0.26, which is 69% below median its 10-year median of 0.85 and 36.6% below the Healthcare Providers & Services industry median of 0.41. Monsenso AS's overall GF Score™ is 27/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current Debt-to-Equity is 0.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.29 is trading 96% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
Debt-to-Equity: 0.26 (69% below median its 10-year median of 0.85)
GF Value™: kr0.15 vs. price of kr0.29 (96% above fair value)
Industry Position: 36.6% below the Healthcare Providers & Services median (#209 of 557)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
27GF Score
Get the complete analysis for OCSE:MONSO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
